JP2006519199A - ２型糖尿病およびアテローム性動脈硬化症の治療のためのｐｐａｒモジュレーターとしての４−（３−（２−フェニル−オキサゾール−４−イルメトキシ）−シクロヘキシルオキシ）−ブタン酸誘導体および関連化合物 - Google Patents

Info

Publication number

JP2006519199A

JP2006519199A JP2006501892A JP2006501892A JP2006519199A JP 2006519199 A JP2006519199 A JP 2006519199A JP 2006501892 A JP2006501892 A JP 2006501892A JP 2006501892 A JP2006501892 A JP 2006501892A JP 2006519199 A JP2006519199 A JP 2006519199A

Authority

JP

Japan

Prior art keywords

alkyl

methyl

ylmethoxy

cyclohexyloxy

phenyl

Prior art date

2003-02-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 176
• 238000011282 treatment Methods 0.000 title claims abstract description 22
• 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 8
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title description 27
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title description 27
• 201000001320 Atherosclerosis Diseases 0.000 title description 5
• MSZHFMAFAHIHRC-UHFFFAOYSA-N 4-[3-[(2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxybutanoic acid Chemical class C1C(OCCCC(=O)O)CCCC1OCC1=COC(C=2C=CC=CC=2)=N1 MSZHFMAFAHIHRC-UHFFFAOYSA-N 0.000 title 1
• 150000003839 salts Chemical class 0.000 claims abstract description 16
• 230000002265 prevention Effects 0.000 claims abstract description 15
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 6
• 239000008103 glucose Substances 0.000 claims abstract description 6
• 230000004129 fatty acid metabolism Effects 0.000 claims abstract 3
• 239000000203 mixture Substances 0.000 claims description 78
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 74
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
• 229910052739 hydrogen Inorganic materials 0.000 claims description 19
• 230000000694 effects Effects 0.000 claims description 17
• 239000003814 drug Substances 0.000 claims description 16
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
• 229910052799 carbon Inorganic materials 0.000 claims description 12
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 11
• 125000004432 carbon atom Chemical group C* 0.000 claims description 8
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 8
• 208000030159 metabolic disease Diseases 0.000 claims description 6
• 238000002156 mixing Methods 0.000 claims description 6
• 229910052740 iodine Inorganic materials 0.000 claims description 5
• 150000002632 lipids Chemical class 0.000 claims description 5
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
• 206010022489 Insulin Resistance Diseases 0.000 claims description 4
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
• 239000003472 antidiabetic agent Substances 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 4
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
• 125000003342 alkenyl group Chemical group 0.000 claims description 3
• 125000000217 alkyl group Chemical group 0.000 claims description 3
• 229940125708 antidiabetic agent Drugs 0.000 claims description 3
• 125000001624 naphthyl group Chemical group 0.000 claims description 3
• 229910052760 oxygen Inorganic materials 0.000 claims description 3
• 229910052717 sulfur Inorganic materials 0.000 claims description 3
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
• 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
• 229930192474 thiophene Natural products 0.000 claims description 2
• 238000000034 method Methods 0.000 abstract description 20
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 13
• 239000002253 acid Substances 0.000 abstract description 11
• 102000004877 Insulin Human genes 0.000 abstract description 8
• 108090001061 Insulin Proteins 0.000 abstract description 8
• 229940125396 insulin Drugs 0.000 abstract description 6
• 238000002360 preparation method Methods 0.000 abstract description 6
• 125000004350 aryl cycloalkyl group Chemical group 0.000 abstract description 2
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
• -1 cyclohexane-1,3-diyl Chemical group 0.000 description 126
• 238000006243 chemical reaction Methods 0.000 description 95
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 73
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 62
• 239000000243 solution Substances 0.000 description 51
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 45
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
• KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 38
• 210000004027 cell Anatomy 0.000 description 37
• 239000002904 solvent Substances 0.000 description 36
• 230000015572 biosynthetic process Effects 0.000 description 32
• 239000012074 organic phase Substances 0.000 description 32
• 238000003786 synthesis reaction Methods 0.000 description 32
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 26
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
• 102000023984 PPAR alpha Human genes 0.000 description 26
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
• 239000004480 active ingredient Substances 0.000 description 25
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 25
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 24
• 239000013612 plasmid Substances 0.000 description 24
• 108010016731 PPAR gamma Proteins 0.000 description 22
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 21
• 235000019260 propionic acid Nutrition 0.000 description 21
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 20
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
• 239000000556 agonist Substances 0.000 description 20
• 108060001084 Luciferase Proteins 0.000 description 19
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
• 239000000741 silica gel Substances 0.000 description 18
• 229910002027 silica gel Inorganic materials 0.000 description 18
• BCKQCTMFFSSHIB-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CI Chemical compound CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CI BCKQCTMFFSSHIB-UHFFFAOYSA-N 0.000 description 17
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
• 239000012230 colorless oil Substances 0.000 description 17
• 239000007787 solid Substances 0.000 description 17
• 239000005089 Luciferase Substances 0.000 description 16
• 238000003556 assay Methods 0.000 description 16
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 16
• 229910000104 sodium hydride Inorganic materials 0.000 description 15
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
• 102000000536 PPAR gamma Human genes 0.000 description 14
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 14
• FSEUPUDHEBLWJY-HWKANZROSA-N diacetylmonoxime Chemical compound CC(=O)C(\C)=N\O FSEUPUDHEBLWJY-HWKANZROSA-N 0.000 description 14
• 230000008569 process Effects 0.000 description 14
• 239000012312 sodium hydride Substances 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
• 235000019341 magnesium sulphate Nutrition 0.000 description 13
• 239000000725 suspension Substances 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• 239000004146 Propane-1,2-diol Substances 0.000 description 11
• 238000003818 flash chromatography Methods 0.000 description 11
• 239000001257 hydrogen Substances 0.000 description 11
• 239000008194 pharmaceutical composition Substances 0.000 description 11
• 229960004063 propylene glycol Drugs 0.000 description 11
• FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 11
• 108010028924 PPAR alpha Proteins 0.000 description 10
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
• 239000003921 oil Substances 0.000 description 10
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 235000013772 propylene glycol Nutrition 0.000 description 10
• 239000011541 reaction mixture Substances 0.000 description 10
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• 102100039556 Galectin-4 Human genes 0.000 description 9
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
• BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 239000012285 osmium tetroxide Substances 0.000 description 9
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
• 108020001507 fusion proteins Proteins 0.000 description 8
• 102000037865 fusion proteins Human genes 0.000 description 8
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
• 238000003756 stirring Methods 0.000 description 8
• 239000003826 tablet Substances 0.000 description 8
• BNCNAQNTIYCMGB-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=C(C=2C=CC=CC=2)O1 BNCNAQNTIYCMGB-UHFFFAOYSA-N 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 239000003112 inhibitor Substances 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 229910052938 sodium sulfate Inorganic materials 0.000 description 7
• 235000011152 sodium sulphate Nutrition 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• CJXNLKIWHBTWMM-UHFFFAOYSA-N 4-(iodomethyl)-1,3-oxazole Chemical compound ICC1=COC=N1 CJXNLKIWHBTWMM-UHFFFAOYSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
• 208000001126 Keratosis Diseases 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 6
• 101100072644 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) INO2 gene Proteins 0.000 description 6
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 6
• 238000009835 boiling Methods 0.000 description 6
• XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
• 239000012973 diazabicyclooctane Substances 0.000 description 6
• 239000013613 expression plasmid Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 229910052763 palladium Inorganic materials 0.000 description 6
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 6
• 238000010992 reflux Methods 0.000 description 6
• 239000011734 sodium Substances 0.000 description 6
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 6
• IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
• NFWPTDKJPGHAIQ-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound OC(=O)C(C)OCC1=CC=C(C(F)(F)F)C=C1 NFWPTDKJPGHAIQ-UHFFFAOYSA-N 0.000 description 5
• DQFNFCZJCTWYGP-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound ICC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 DQFNFCZJCTWYGP-UHFFFAOYSA-N 0.000 description 5
• LAKXJTRDJPBSAS-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 LAKXJTRDJPBSAS-UHFFFAOYSA-N 0.000 description 5
• 206010020649 Hyperkeratosis Diseases 0.000 description 5
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
• 229930182816 L-glutamine Natural products 0.000 description 5
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
• 229940100389 Sulfonylurea Drugs 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 238000004007 reversed phase HPLC Methods 0.000 description 5
• NTMNMWBNRDKKEE-UHFFFAOYSA-N 2-(2,4-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 NTMNMWBNRDKKEE-UHFFFAOYSA-N 0.000 description 4
• ZVJBPHMCBRHVEV-UHFFFAOYSA-N 2-hydroxyiminopentan-3-one Chemical compound CCC(=O)C(C)=NO ZVJBPHMCBRHVEV-UHFFFAOYSA-N 0.000 description 4
• FTGLOGXZTCJWQV-RCCQNZRSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(3-methoxyphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=C(OC)C=CC=2)=N1 FTGLOGXZTCJWQV-RCCQNZRSSA-N 0.000 description 4
• YXXSKPPRENBIBF-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-GPTJOGTASA-N 0.000 description 4
• JEMQSYWUSRUZQU-UHFFFAOYSA-N 3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexan-1-ol Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(O)C1 JEMQSYWUSRUZQU-UHFFFAOYSA-N 0.000 description 4
• WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical group COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 4
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 4
• AONKVWHDUVHQSZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 AONKVWHDUVHQSZ-UHFFFAOYSA-N 0.000 description 4
• QGKGLJHQIRRWES-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=C(C)O1 QGKGLJHQIRRWES-UHFFFAOYSA-N 0.000 description 4
• WZOMSQRBEXCMRP-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=C(OC)C=CC=2)=N1 WZOMSQRBEXCMRP-UHFFFAOYSA-N 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 108090000331 Firefly luciferases Proteins 0.000 description 4
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 108010084455 Zeocin Proteins 0.000 description 4
• 229960000583 acetic acid Drugs 0.000 description 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 239000003054 catalyst Substances 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 238000001816 cooling Methods 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• STXQYTGSIQCKFA-UHFFFAOYSA-N ethyl 2-amino-4-methyl-3-oxopentanoate;hydrochloride Chemical compound Cl.CCOC(=O)C(N)C(=O)C(C)C STXQYTGSIQCKFA-UHFFFAOYSA-N 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
• 229960003105 metformin Drugs 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
• CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
• MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• YPINLRNGSGGJJT-JXMROGBWSA-N (2e)-2-hydroxyimino-1-phenylpropan-1-one Chemical compound O\N=C(/C)C(=O)C1=CC=CC=C1 YPINLRNGSGGJJT-JXMROGBWSA-N 0.000 description 3
• YXXSKPPRENBIBF-GSLIJJQTSA-N (2s)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-GSLIJJQTSA-N 0.000 description 3
• FDBGURXQLIASAR-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methyl-4-[(3-prop-2-enoxycyclohexyl)oxymethyl]-1,3-oxazole Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(OCC=C)C1 FDBGURXQLIASAR-UHFFFAOYSA-N 0.000 description 3
• MFDBEIHCSIVRCN-UXHICEINSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoic acid Chemical compound C1[C@H](OCC=C(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MFDBEIHCSIVRCN-UXHICEINSA-N 0.000 description 3
• CMINROMQYDFVKZ-OHAXFNJZSA-N 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybutanoic acid Chemical compound C1[C@H](OCCC(CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 CMINROMQYDFVKZ-OHAXFNJZSA-N 0.000 description 3
• WEWPHAAWLKAJKC-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-5-phenyl-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=C(C=2C=CC=CC=2)O1 WEWPHAAWLKAJKC-UHFFFAOYSA-N 0.000 description 3
• XJKVVHCZKAADFP-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(C)=C(CI)N=2)=C1 XJKVVHCZKAADFP-UHFFFAOYSA-N 0.000 description 3
• XWACKBMPGJMLFJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(3-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 XWACKBMPGJMLFJ-UHFFFAOYSA-N 0.000 description 3
• ACMFBGDVEITOFZ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 ACMFBGDVEITOFZ-UHFFFAOYSA-N 0.000 description 3
• OJSUKGKXAPQITL-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 OJSUKGKXAPQITL-UHFFFAOYSA-N 0.000 description 3
• SLYIGTWFTNDINH-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 SLYIGTWFTNDINH-UHFFFAOYSA-N 0.000 description 3
• XFLMZIVSUSURBJ-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-naphthalen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 XFLMZIVSUSURBJ-UHFFFAOYSA-N 0.000 description 3
• 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• NIVGNNIVMXYXFG-UHFFFAOYSA-N 4-methyl-2-(4-methylphenyl)-3-oxido-5-phenyl-1,3-oxazol-3-ium Chemical compound [O-][N+]=1C(C)=C(C=2C=CC=CC=2)OC=1C1=CC=C(C)C=C1 NIVGNNIVMXYXFG-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• OYAVEBCIIKQNLQ-VQTJNVASSA-N CC1=C(CO[C@@H](CCC2)C[C@@H]2OCOC(C2CC2)=O)N=C(C2=CC=CC(C)=C2)O1 Chemical compound CC1=C(CO[C@@H](CCC2)C[C@@H]2OCOC(C2CC2)=O)N=C(C2=CC=CC(C)=C2)O1 OYAVEBCIIKQNLQ-VQTJNVASSA-N 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• 240000008886 Ceratonia siliqua Species 0.000 description 3
• 235000013912 Ceratonia siliqua Nutrition 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 102000016267 Leptin Human genes 0.000 description 3
• 108010092277 Leptin Proteins 0.000 description 3
• 241000713333 Mouse mammary tumor virus Species 0.000 description 3
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
• 229940126033 PPAR agonist Drugs 0.000 description 3
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 3
• 241000254064 Photinus pyralis Species 0.000 description 3
• 102000004257 Potassium Channel Human genes 0.000 description 3
• 108010052090 Renilla Luciferases Proteins 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 230000023852 carbohydrate metabolic process Effects 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• SMAOVIHJZYGLNT-UHFFFAOYSA-N ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate Chemical compound CCOC(=O)C(=NO)C(=O)C(C)C SMAOVIHJZYGLNT-UHFFFAOYSA-N 0.000 description 3
• OCJKUQIPRNZDTK-UHFFFAOYSA-N ethyl 4,4,4-trifluoro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)C(F)(F)F OCJKUQIPRNZDTK-UHFFFAOYSA-N 0.000 description 3
• HDTDHYKMFULBIB-UHFFFAOYSA-N ethyl 4-methyl-2-[(4-methylbenzoyl)amino]-3-oxopentanoate Chemical compound CCOC(=O)C(C(=O)C(C)C)NC(=O)C1=CC=C(C)C=C1 HDTDHYKMFULBIB-UHFFFAOYSA-N 0.000 description 3
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
• 229940039781 leptin Drugs 0.000 description 3
• 230000037356 lipid metabolism Effects 0.000 description 3
• 239000012280 lithium aluminium hydride Substances 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 235000011181 potassium carbonates Nutrition 0.000 description 3
• 108020001213 potassium channel Proteins 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 229960002354 repaglinide Drugs 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 208000017520 skin disease Diseases 0.000 description 3
• RCNVIAZJJPKRLG-UHFFFAOYSA-N tert-butyl-diphenyl-propoxysilane Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)(OCCC)C1=CC=CC=C1 RCNVIAZJJPKRLG-UHFFFAOYSA-N 0.000 description 3
• DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
• AQKACENWDQZESU-PBOULFJWSA-N (2E,4E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)-hepta-2,4-dienamide Chemical compound CC(C)CNC(=O)\C=C\C=C\CCC1=CC=C2OCOC2=C1 AQKACENWDQZESU-PBOULFJWSA-N 0.000 description 2
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
• DFJTYRPOKMYJLU-YIKNKFAXSA-N (2r)-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C2C=CC=CC2=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 DFJTYRPOKMYJLU-YIKNKFAXSA-N 0.000 description 2
• YXXSKPPRENBIBF-BFLUCZKCSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 YXXSKPPRENBIBF-BFLUCZKCSA-N 0.000 description 2
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
• HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
• KQDQZEZWWRPNQH-UHFFFAOYSA-N 1,3-diazabicyclo[2.2.2]octane Chemical compound C1CC2CCN1CN2 KQDQZEZWWRPNQH-UHFFFAOYSA-N 0.000 description 2
• BKZHSJNLPPAJKB-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea;hydrochloride Chemical compound Cl.C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 BKZHSJNLPPAJKB-UHFFFAOYSA-N 0.000 description 2
• IKSNDOVDVVPSMA-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C=C1 IKSNDOVDVVPSMA-UHFFFAOYSA-N 0.000 description 2
• PFFCLJDVINXVNR-RBUKOAKNSA-N 1-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]cyclopropane-1-carboxylic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC1(C(O)=O)CC1 PFFCLJDVINXVNR-RBUKOAKNSA-N 0.000 description 2
• GIYZJSLQVOWCAR-UHFFFAOYSA-N 1-cyclohexyl-2-hydroxyiminopropan-1-one Chemical compound ON=C(C)C(=O)C1CCCCC1 GIYZJSLQVOWCAR-UHFFFAOYSA-N 0.000 description 2
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
• UEJHHKGNCWUBHD-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 UEJHHKGNCWUBHD-UHFFFAOYSA-N 0.000 description 2
• ZDVRPKUWYQVVDX-UHFFFAOYSA-N 2-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=CC=C1C=O ZDVRPKUWYQVVDX-UHFFFAOYSA-N 0.000 description 2
• VNLHFRIFAMCIHY-UHFFFAOYSA-N 2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]acetaldehyde Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(CC=O)C1 VNLHFRIFAMCIHY-UHFFFAOYSA-N 0.000 description 2
• ISSPREHQQMHYMA-JCVDRHSJSA-N 2-ethoxy-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 ISSPREHQQMHYMA-JCVDRHSJSA-N 0.000 description 2
• MFFJJGUOJQGPTJ-ZOAFEQKISA-N 2-methoxy-3-[(1r,3s)-3-[(5-methyl-2-naphthalen-2-yl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C3C=CC=CC3=CC=2)=N1 MFFJJGUOJQGPTJ-ZOAFEQKISA-N 0.000 description 2
• NHOYTVJCIVUNRF-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 NHOYTVJCIVUNRF-PZEDNMLSSA-N 0.000 description 2
• UXFXUVAMGZQVTO-IVAAQHKWSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 UXFXUVAMGZQVTO-IVAAQHKWSA-N 0.000 description 2
• SFHMXWCADKXPHU-FPHLKLNRSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 SFHMXWCADKXPHU-FPHLKLNRSA-N 0.000 description 2
• IFZLLUQRQZPTQW-GWFKTICUSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 IFZLLUQRQZPTQW-GWFKTICUSA-N 0.000 description 2
• CBRFSDWTRQSMPP-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 CBRFSDWTRQSMPP-PZEDNMLSSA-N 0.000 description 2
• CHDMTTYVZFBRNZ-PZEDNMLSSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 CHDMTTYVZFBRNZ-PZEDNMLSSA-N 0.000 description 2
• VQVRENONUXYEPP-GARIHTGFSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 VQVRENONUXYEPP-GARIHTGFSA-N 0.000 description 2
• NDGKYAYGLGCZBS-GARIHTGFSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C(=CC=CC=2C)C)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 NDGKYAYGLGCZBS-GARIHTGFSA-N 0.000 description 2
• QYQCDGRJGUGQGP-IVAAQHKWSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2C)C)=N1 QYQCDGRJGUGQGP-IVAAQHKWSA-N 0.000 description 2
• GEGSPMOQMWOBPJ-RJKSWSIASA-N 3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC)C=CC=2)=N1 GEGSPMOQMWOBPJ-RJKSWSIASA-N 0.000 description 2
• FQYFZVCWPANGTJ-RCCQNZRSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(C)=CC=2)=N1 FQYFZVCWPANGTJ-RCCQNZRSSA-N 0.000 description 2
• WTKSOBVOIYJFMS-FQTTXOOSSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 WTKSOBVOIYJFMS-FQTTXOOSSA-N 0.000 description 2
• UIIGBNOUEQZOJI-VKWYCSODSA-N 3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C(=CC=CC=2)C(F)(F)F)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 UIIGBNOUEQZOJI-VKWYCSODSA-N 0.000 description 2
• LAWKKFGROHFRNS-VIHOQOLSSA-N 3-[(1r,3s)-3-[[5-methyl-2-(2-naphthalen-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C=2C=C3C=CC=CC3=CC=2)=N1 LAWKKFGROHFRNS-VIHOQOLSSA-N 0.000 description 2
• RNHRRUOQVQVUIT-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 RNHRRUOQVQVUIT-RJKSWSIASA-N 0.000 description 2
• WVUWDMQFNWJJGO-JCVDRHSJSA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 WVUWDMQFNWJJGO-JCVDRHSJSA-N 0.000 description 2
• QXBYCFUHZXNZGG-NXRUOVBSSA-N 3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 QXBYCFUHZXNZGG-NXRUOVBSSA-N 0.000 description 2
• YTAGWZUNCHKJNH-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 YTAGWZUNCHKJNH-KTVLMBSMSA-N 0.000 description 2
• UKSBRLCFLVAJNA-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 UKSBRLCFLVAJNA-KTVLMBSMSA-N 0.000 description 2
• RRSMWVVGYPRIGB-KTVLMBSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 RRSMWVVGYPRIGB-KTVLMBSMSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• SOINZDZUVFPFLV-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-(5-methylfuran-2-yl)-1,3-oxazole Chemical compound O1C(C)=CC=C1C1=NC(CI)=C(C)O1 SOINZDZUVFPFLV-UHFFFAOYSA-N 0.000 description 2
• RIPPLGSFZLWCCG-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 RIPPLGSFZLWCCG-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
• NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 2
• HSJYZRUAFNGACR-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 HSJYZRUAFNGACR-UHFFFAOYSA-N 0.000 description 2
• OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• 229940123208 Biguanide Drugs 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 230000004568 DNA-binding Effects 0.000 description 2
• 201000004624 Dermatitis Diseases 0.000 description 2
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 102000018997 Growth Hormone Human genes 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 2
• 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 2
• 241000701806 Human papillomavirus Species 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 239000003810 Jones reagent Substances 0.000 description 2
• 208000002260 Keloid Diseases 0.000 description 2
• 206010023330 Keloid scar Diseases 0.000 description 2
• 238000008214 LDL Cholesterol Methods 0.000 description 2
• 229940086609 Lipase inhibitor Drugs 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
• 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• 206010033307 Overweight Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229940123464 Thiazolidinedione Drugs 0.000 description 2
• 102000006601 Thymidine Kinase Human genes 0.000 description 2
• 108020004440 Thymidine kinase Proteins 0.000 description 2
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
• WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 102000005630 Urocortins Human genes 0.000 description 2
• 108010059705 Urocortins Proteins 0.000 description 2
• HQTZHHDTBSHTDM-CVEARBPZSA-N [(1s,3r)-3-prop-2-enoxycyclohexyl]oxymethylbenzene Chemical compound C1[C@H](OCC=C)CCC[C@@H]1OCC1=CC=CC=C1 HQTZHHDTBSHTDM-CVEARBPZSA-N 0.000 description 2
• QJHAWRGKDNXWIY-UHFFFAOYSA-N [2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazol-4-yl]methanol Chemical compound OCC1=C(C(C)C)OC(C=2C=CC(C)=CC=2)=N1 QJHAWRGKDNXWIY-UHFFFAOYSA-N 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 229960002632 acarbose Drugs 0.000 description 2
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 150000001350 alkyl halides Chemical class 0.000 description 2
• 150000001351 alkyl iodides Chemical class 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 229940025084 amphetamine Drugs 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000003110 anti-inflammatory effect Effects 0.000 description 2
• 239000000883 anti-obesity agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 229940125710 antiobesity agent Drugs 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
• 239000003613 bile acid Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000004296 chiral HPLC Methods 0.000 description 2
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 229960004597 dexfenfluramine Drugs 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 208000016097 disease of metabolism Diseases 0.000 description 2
• 238000010931 ester hydrolysis Methods 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• XWKOSAYDZJXYQO-UHFFFAOYSA-N ethyl 2-(4-methylphenyl)-5-propan-2-yl-1,3-oxazole-4-carboxylate Chemical compound O1C(C(C)C)=C(C(=O)OCC)N=C1C1=CC=C(C)C=C1 XWKOSAYDZJXYQO-UHFFFAOYSA-N 0.000 description 2
• MTCMFVTVXAOHNQ-UHFFFAOYSA-N ethyl 2-(bromomethyl)prop-2-enoate Chemical compound CCOC(=O)C(=C)CBr MTCMFVTVXAOHNQ-UHFFFAOYSA-N 0.000 description 2
• MVHIIPHBVXIUCL-YADHBBJMSA-N ethyl 2-ethyl-4-[(1r,3s)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybut-2-enoate Chemical compound C1[C@H](OCC=C(CC)C(=O)OCC)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 MVHIIPHBVXIUCL-YADHBBJMSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 229940125753 fibrate Drugs 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 230000006870 function Effects 0.000 description 2
• 238000007306 functionalization reaction Methods 0.000 description 2
• 210000004051 gastric juice Anatomy 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 229960004580 glibenclamide Drugs 0.000 description 2
• 229960004346 glimepiride Drugs 0.000 description 2
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
• 229960001381 glipizide Drugs 0.000 description 2
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
• 102000054223 human PPARA Human genes 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
• 239000004026 insulin derivative Substances 0.000 description 2
• 239000000543 intermediate Substances 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 210000001117 keloid Anatomy 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 229940060975 lantus Drugs 0.000 description 2
• 229960004844 lovastatin Drugs 0.000 description 2
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 229950004994 meglitinide Drugs 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 229960005095 pioglitazone Drugs 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• 235000015320 potassium carbonate Nutrition 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 229960004586 rosiglitazone Drugs 0.000 description 2
• 238000007493 shaping process Methods 0.000 description 2
• 201000010153 skin papilloma Diseases 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 235000009518 sodium iodide Nutrition 0.000 description 2
• 235000010288 sodium nitrite Nutrition 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000011877 solvent mixture Substances 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 229960005371 tolbutamide Drugs 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 125000004665 trialkylsilyl group Chemical group 0.000 description 2
• VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 2
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 239000000777 urocortin Substances 0.000 description 2
• MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 2
• DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
• QKCWUSGSHMIBCN-SQJMNOBHSA-N (1r,3s)-3-(trityloxymethyl)cyclohexan-1-ol Chemical compound C1[C@H](O)CCC[C@@H]1COC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 QKCWUSGSHMIBCN-SQJMNOBHSA-N 0.000 description 1
• RFCYVWGCOXVSBD-OLZOCXBDSA-N (1r,3s)-3-phenylmethoxycyclohexan-1-ol Chemical compound C1[C@H](O)CCC[C@@H]1OCC1=CC=CC=C1 RFCYVWGCOXVSBD-OLZOCXBDSA-N 0.000 description 1
• SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
• HXAVIGJRKGAOAC-GEWUYGHSSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxymethyl]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)COCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 HXAVIGJRKGAOAC-GEWUYGHSSA-N 0.000 description 1
• MBFPZJPLBYFTFI-ZRRKCSAHSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CO[C@@H]2C[C@@H](CCC2)OC[C@@H](OCC=2C=CC(=CC=2)C(F)(F)F)C(O)=O)=C(C)O1 MBFPZJPLBYFTFI-ZRRKCSAHSA-N 0.000 description 1
• ABCQNYILLLXKLF-JBRSBNLGSA-N (2r)-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@H](CO[C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C=CC=1)C(F)(F)F)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 ABCQNYILLLXKLF-JBRSBNLGSA-N 0.000 description 1
• HXAVIGJRKGAOAC-RWUBSVTLSA-N (2s)-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxymethyl]cyclohexyl]oxy-2-[[4-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H](CO[C@@H]1CCC[C@@H](C1)COCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)C(O)=O)CC1=CC=C(C(F)(F)F)C=C1 HXAVIGJRKGAOAC-RWUBSVTLSA-N 0.000 description 1
• ALSCEGDXFJIYES-YFKPBYRVSA-N (2s)-pyrrolidine-2-carbonitrile Chemical compound N#C[C@@H]1CCCN1 ALSCEGDXFJIYES-YFKPBYRVSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
• OMXRTIUYSHDUTH-UHFFFAOYSA-N 1-(3-ethyl-1-benzofuran-7-yl)piperazine;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(CC)=COC2=C1N1CCNCC1 OMXRTIUYSHDUTH-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• FXFUBSNEYXTGNP-XQFMJXHWSA-N 1-[tert-butyl(dimethyl)silyl]oxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropan-2-ol Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(O)CO[Si](C)(C)C(C)(C)C)C1 FXFUBSNEYXTGNP-XQFMJXHWSA-N 0.000 description 1
• DEFNUDNHTUZJAL-UHFFFAOYSA-N 1-bromo-2-methylprop-1-ene Chemical compound CC(C)=CBr DEFNUDNHTUZJAL-UHFFFAOYSA-N 0.000 description 1
• IOCSSHWOWKBYMI-BCQQZXIPSA-N 1-bromo-3-(trifluoromethyl)benzene;2-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound FC(F)(F)C1=CC=CC(Br)=C1.O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)CC1=CC=CC(C(F)(F)F)=C1 IOCSSHWOWKBYMI-BCQQZXIPSA-N 0.000 description 1
• IZWIMRSEBZHUAD-UHFFFAOYSA-N 1-prop-2-ynoxypropan-1-ol Chemical compound C(C#C)OC(CC)O IZWIMRSEBZHUAD-UHFFFAOYSA-N 0.000 description 1
• GISVICWQYMUPJF-UHFFFAOYSA-N 2,4-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(C)=C1 GISVICWQYMUPJF-UHFFFAOYSA-N 0.000 description 1
• QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 1
• ARNCUSIEBKDVTJ-UHFFFAOYSA-N 2-(2,6-dimethylphenyl)-4-(iodomethyl)-5-methyl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2C(=CC=CC=2C)C)=N1 ARNCUSIEBKDVTJ-UHFFFAOYSA-N 0.000 description 1
• ANFNOYNIAFXHFF-RJKSWSIASA-N 2-(2-methylpropoxy)-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 ANFNOYNIAFXHFF-RJKSWSIASA-N 0.000 description 1
• HAWSTCYOCUMUIJ-UHFFFAOYSA-N 2-(4-methylphenyl)-5-(trifluoromethyl)-1,3-oxazole Chemical compound CC1=CC=C(C=C1)C=1OC(=CN=1)C(F)(F)F HAWSTCYOCUMUIJ-UHFFFAOYSA-N 0.000 description 1
• VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 1
• CKKXBBNLSRIAOY-VEPNZUSMSA-N 2-[(2,5-dimethylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC(C)=CC=C1C CKKXBBNLSRIAOY-VEPNZUSMSA-N 0.000 description 1
• ARGSBCMRQQCCAY-QDSWCARHSA-N 2-[(3-methoxyphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound COC1=CC=CC(COC(CO[C@H]2C[C@H](CCC2)OCC2=C(OC(=N2)C=2C=C(C)C=CC=2)C)C(O)=O)=C1 ARGSBCMRQQCCAY-QDSWCARHSA-N 0.000 description 1
• WAYZWXLEBGEFKA-ZDCXKQOISA-N 2-[(4-tert-butylphenyl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C(C)(C)C)C=C1 WAYZWXLEBGEFKA-ZDCXKQOISA-N 0.000 description 1
• WQJIOTWPJDPPHW-RCCQNZRSSA-N 2-[(5-chlorothiophen-2-yl)methoxy]-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(Cl)S1 WQJIOTWPJDPPHW-RCCQNZRSSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• DKDSZOOZDBVUAH-UHFFFAOYSA-N 2-[2-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxyethyl]pentanoic acid Chemical compound C1C(OCCC(CCC)C(O)=O)CCCC1OCC1=C(C)OC(C=2C=CC(F)=CC=2)=N1 DKDSZOOZDBVUAH-UHFFFAOYSA-N 0.000 description 1
• UJGBTZUTZSMGCO-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC UJGBTZUTZSMGCO-UHFFFAOYSA-N 0.000 description 1
• FAUGURYODQJLOV-UHFFFAOYSA-N 2-[4-(iodomethyl)-5-methylnaphthalen-2-yl]-1,3-oxazole Chemical compound C=1C(CI)=C2C(C)=CC=CC2=CC=1C1=NC=CO1 FAUGURYODQJLOV-UHFFFAOYSA-N 0.000 description 1
• SDHLTWJVIIREOF-GOGAEGRDSA-N 2-[[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxymethyl]-3-[3-(trifluoromethyl)phenyl]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)CC1=CC=CC(C(F)(F)F)=C1 SDHLTWJVIIREOF-GOGAEGRDSA-N 0.000 description 1
• ODPWGDNCQVMMNT-ZOAFEQKISA-N 2-but-2-ynoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC#CC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 ODPWGDNCQVMMNT-ZOAFEQKISA-N 0.000 description 1
• ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
• MQTKXCOGYOYAMW-UHFFFAOYSA-N 2-chloro-5-(chloromethyl)thiophene Chemical compound ClCC1=CC=C(Cl)S1 MQTKXCOGYOYAMW-UHFFFAOYSA-N 0.000 description 1
• WOAKKLLAVUWBDI-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 WOAKKLLAVUWBDI-IVAAQHKWSA-N 0.000 description 1
• PESRNTYCYSEXIL-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC)C=CC=2)=N1 PESRNTYCYSEXIL-KTVLMBSMSA-N 0.000 description 1
• YDFDBYWGPSSEBO-WQFBUZOZSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-(2-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C)=N1 YDFDBYWGPSSEBO-WQFBUZOZSA-N 0.000 description 1
• WATQRZILZRLBLA-LDJQHZOJSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 WATQRZILZRLBLA-LDJQHZOJSA-N 0.000 description 1
• OUCXLLHJTMFYRI-PTHSTZKBSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 OUCXLLHJTMFYRI-PTHSTZKBSA-N 0.000 description 1
• WKJHFRSWZKSOMW-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 WKJHFRSWZKSOMW-KTVLMBSMSA-N 0.000 description 1
• SJOPWTFCLAXZPR-KTVLMBSMSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 SJOPWTFCLAXZPR-KTVLMBSMSA-N 0.000 description 1
• ULNKGCWASNUVLP-ZOAFEQKISA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 ULNKGCWASNUVLP-ZOAFEQKISA-N 0.000 description 1
• JQMGVQWWVXUCCO-QRFGBVCESA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 JQMGVQWWVXUCCO-QRFGBVCESA-N 0.000 description 1
• OXSWNMGVILHANM-QJNHQHDKSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 OXSWNMGVILHANM-QJNHQHDKSA-N 0.000 description 1
• JNORNIVLLYTVNH-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C=CC=2)C(F)(F)F)=N1 JNORNIVLLYTVNH-IVAAQHKWSA-N 0.000 description 1
• URGNWGPYJKRMNR-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(OC(F)(F)F)=CC=2)=N1 URGNWGPYJKRMNR-IVAAQHKWSA-N 0.000 description 1
• XLMLIXHOFLDWEY-IVAAQHKWSA-N 2-ethoxy-3-[(1r,3s)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(F)(F)F)=N1 XLMLIXHOFLDWEY-IVAAQHKWSA-N 0.000 description 1
• IBIMXAAZWOQNDX-UHFFFAOYSA-N 2-ethyl-3-(iodomethyl)-5-(4-methylphenyl)-1h-pyrrole Chemical compound ICC1=C(CC)NC(C=2C=CC(C)=CC=2)=C1 IBIMXAAZWOQNDX-UHFFFAOYSA-N 0.000 description 1
• ZYQGJKOCXWIBCS-IVAAQHKWSA-N 2-methoxy-3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxypropanoic acid Chemical compound C1[C@H](OCC(OC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 ZYQGJKOCXWIBCS-IVAAQHKWSA-N 0.000 description 1
• ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 2-methyl-1,3-oxazole Chemical compound CC1=NC=CO1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
• YCOXJFAUNLRWPU-UHFFFAOYSA-N 2-methyl-n,n-dipropyl-9-(2,4,6-trimethylphenyl)pyrimido[4,5-b]indol-4-amine Chemical compound C12=CC=CC=C2C=2C(N(CCC)CCC)=NC(C)=NC=2N1C1=C(C)C=C(C)C=C1C YCOXJFAUNLRWPU-UHFFFAOYSA-N 0.000 description 1
• PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 description 1
• LCRCBXLHWTVPEQ-UHFFFAOYSA-N 2-phenylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1 LCRCBXLHWTVPEQ-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
• FQEVHRCPXFKJHF-UHFFFAOYSA-N 3-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC(C=O)=C1 FQEVHRCPXFKJHF-UHFFFAOYSA-N 0.000 description 1
• RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 1
• NDBUCZOFHAHPIR-KTVLMBSMSA-N 3-[(1r,3s)-3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC=CC=2)=N1 NDBUCZOFHAHPIR-KTVLMBSMSA-N 0.000 description 1
• NOIUCUFRAOHIBH-HXIJRHRVSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-ethoxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC(C)=CC=2)C)=N1 NOIUCUFRAOHIBH-HXIJRHRVSA-N 0.000 description 1
• AUDSTWRPKXPLOV-ZKTCVHQMSA-N 3-[(1r,3s)-3-[[2-(2,4-dimethylphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-ethoxypropanoic acid Chemical compound C1[C@H](OCC(OCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C(=CC(C)=CC=2)C)=N1 AUDSTWRPKXPLOV-ZKTCVHQMSA-N 0.000 description 1
• GVQGZAJWXFQBRI-RCCQNZRSSA-N 3-[(1r,3s)-3-[[2-(2,6-dimethylphenyl)-5-ethyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2C)C)=N1 GVQGZAJWXFQBRI-RCCQNZRSSA-N 0.000 description 1
• KXFCNFIFTNZBHX-ZOAFEQKISA-N 3-[(1r,3s)-3-[[2-(3-methoxyphenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound COC1=CC=CC(C=2OC(C)=C(CO[C@@H]3C[C@@H](CCC3)OCC(OCC(C)C)C(O)=O)N=2)=C1 KXFCNFIFTNZBHX-ZOAFEQKISA-N 0.000 description 1
• KWGGYADYRRWBED-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(3-methoxyphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C=C(OC)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 KWGGYADYRRWBED-GARIHTGFSA-N 0.000 description 1
• UKFJLKWJFZFIAC-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-ethyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-methoxypropanoic acid Chemical compound CCC=1OC(C=2C=CC(C)=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OC)C(O)=O)C1 UKFJLKWJFZFIAC-GARIHTGFSA-N 0.000 description 1
• WOOTXPMIZUFJRQ-NCHORFDRSA-N 3-[(1r,3s)-3-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(CC)OC(C=2C(=CC=CC=2)C(F)(F)F)=N1 WOOTXPMIZUFJRQ-NCHORFDRSA-N 0.000 description 1
• ITDRKCOOVMPGGY-ZOAFEQKISA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylprop-2-enoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(=C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 ITDRKCOOVMPGGY-ZOAFEQKISA-N 0.000 description 1
• TTXMWZQHPXTCCU-VEPNZUSMSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(3-phenylprop-2-enoxy)propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC=CC1=CC=CC=C1 TTXMWZQHPXTCCU-VEPNZUSMSA-N 0.000 description 1
• NTSSMZLSKXODID-QDSWCARHSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[(4-methylphenyl)methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=C(C)C=C1 NTSSMZLSKXODID-QDSWCARHSA-N 0.000 description 1
• GPUNDHQYVUIIKS-MXKXXCEUSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[2-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC=C1C(F)(F)F GPUNDHQYVUIIKS-MXKXXCEUSA-N 0.000 description 1
• UGJIQXNPMSEYSB-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-[[3-(trifluoromethyl)phenyl]methoxy]propanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC(C(F)(F)F)=C1 UGJIQXNPMSEYSB-GPTJOGTASA-N 0.000 description 1
• RSMWJHBZGDSYBU-JCVDRHSJSA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-pent-2-ynoxypropanoic acid Chemical compound C1[C@H](OCC(OCC#CCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 RSMWJHBZGDSYBU-JCVDRHSJSA-N 0.000 description 1
• DRUJFZBMHLGGOZ-GPTJOGTASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-phenylmethoxypropanoic acid Chemical compound O([C@@H]1CCC[C@@H](C1)OCC=1N=C(OC=1C)C=1C=C(C)C=CC=1)CC(C(O)=O)OCC1=CC=CC=C1 DRUJFZBMHLGGOZ-GPTJOGTASA-N 0.000 description 1
• JSSLXQVFFDMJAQ-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-prop-2-enoxypropanoic acid Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OCC=C)C(O)=O)C1 JSSLXQVFFDMJAQ-RJKSWSIASA-N 0.000 description 1
• XBAHJRILVGQVRV-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-prop-2-ynoxypropanoic acid Chemical compound CC=1OC(C=2C=C(C)C=CC=2)=NC=1CO[C@H]1CCC[C@@H](OCC(OCC#C)C(O)=O)C1 XBAHJRILVGQVRV-RJKSWSIASA-N 0.000 description 1
• JTNVAZIMNQBJFU-RJKSWSIASA-N 3-[(1r,3s)-3-[[5-methyl-2-(3-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(C)C=CC=2)=N1 JTNVAZIMNQBJFU-RJKSWSIASA-N 0.000 description 1
• HDCGYCSLBSXTPX-ZOAFEQKISA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(C)=CC=2)=N1 HDCGYCSLBSXTPX-ZOAFEQKISA-N 0.000 description 1
• UCMCZJXIDLEOMX-YGHPRADISA-N 3-[(1r,3s)-3-[[5-methyl-2-(4-propan-2-ylphenyl)-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-(2-methylpropoxy)propanoic acid Chemical compound C1[C@H](OCC(OCC(C)C)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=CC(=CC=2)C(C)C)=N1 UCMCZJXIDLEOMX-YGHPRADISA-N 0.000 description 1
• CURXXYXICBBGDO-GARIHTGFSA-N 3-[(1r,3s)-3-[[5-methyl-2-[3-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxy-2-propoxypropanoic acid Chemical compound C1[C@H](OCC(OCCC)C(O)=O)CCC[C@@H]1OCC1=C(C)OC(C=2C=C(OC(F)(F)F)C=CC=2)=N1 CURXXYXICBBGDO-GARIHTGFSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
• TWJQZBXURHWBPV-UHFFFAOYSA-N 3-cyclohexyl-1-(4,4-dimethyl-6,7-dihydro-1h-imidazo[4,5-c]pyridin-5-yl)propan-1-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1CC=2NC=NC=2C(C)(C)N1C(=O)CCC1CCCCC1 TWJQZBXURHWBPV-UHFFFAOYSA-N 0.000 description 1
• RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
• VCTKYTBWZTZPHF-UHFFFAOYSA-N 4-(chloromethyl)-5-methyl-2-phenyl-1,3-oxazole Chemical compound ClCC1=C(C)OC(C=2C=CC=CC=2)=N1 VCTKYTBWZTZPHF-UHFFFAOYSA-N 0.000 description 1
• DOSVJMCCPCFNCO-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC=C(CI)N=2)=C1 DOSVJMCCPCFNCO-UHFFFAOYSA-N 0.000 description 1
• OKHGLMQXLUEZMI-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-phenyl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C=2C=CC=CC=2)=C1 OKHGLMQXLUEZMI-UHFFFAOYSA-N 0.000 description 1
• UUOZIINDOMFDBE-UHFFFAOYSA-N 4-(iodomethyl)-2-(3-methoxyphenyl)-5-propan-2-yl-1,3-oxazole Chemical compound COC1=CC=CC(C=2OC(=C(CI)N=2)C(C)C)=C1 UUOZIINDOMFDBE-UHFFFAOYSA-N 0.000 description 1
• CUPROPFTDOKVRM-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methoxyphenyl)-5-methyl-1,3-oxazole Chemical compound C1=CC(OC)=CC=C1C1=NC(CI)=C(C)O1 CUPROPFTDOKVRM-UHFFFAOYSA-N 0.000 description 1
• VBEYNUQRWAKFMV-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NC(CI)=CO1 VBEYNUQRWAKFMV-UHFFFAOYSA-N 0.000 description 1
• OHVWIGRETNBHOI-UHFFFAOYSA-N 4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound C1=CC(C(C)C)=CC=C1C1=NC(CI)=CO1 OHVWIGRETNBHOI-UHFFFAOYSA-N 0.000 description 1
• XHVLHNBJYTXNHA-UHFFFAOYSA-N 4-(iodomethyl)-2-[2-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound FC(F)(F)C1=CC=CC=C1C1=NC(CI)=CO1 XHVLHNBJYTXNHA-UHFFFAOYSA-N 0.000 description 1
• MRSKWSKTUZNPPK-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazole Chemical compound C1=CC(OC(F)(F)F)=CC=C1C1=NC(CI)=CO1 MRSKWSKTUZNPPK-UHFFFAOYSA-N 0.000 description 1
• NYFYEHIGJXMWHU-UHFFFAOYSA-N 4-(iodomethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=NC(CI)=CO1 NYFYEHIGJXMWHU-UHFFFAOYSA-N 0.000 description 1
• AUXXYEOGNXWTJT-UHFFFAOYSA-N 4-(iodomethyl)-2-phenyl-1,3-oxazole Chemical compound ICC1=COC(C=2C=CC=CC=2)=N1 AUXXYEOGNXWTJT-UHFFFAOYSA-N 0.000 description 1
• URSQQDZMMODUMK-UHFFFAOYSA-N 4-(iodomethyl)-5-methyl-2-thiophen-2-yl-1,3-oxazole Chemical compound ICC1=C(C)OC(C=2SC=CC=2)=N1 URSQQDZMMODUMK-UHFFFAOYSA-N 0.000 description 1
• VSJDFQODQBDEHI-UHFFFAOYSA-N 4-[3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexyl]oxybutanoic acid Chemical compound CC=1OC(C=2C=CC(F)=CC=2)=NC=1COC1CCCC(OCCCC(O)=O)C1 VSJDFQODQBDEHI-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• KBIHBGYYYFRDEA-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-methylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(C)=CC=2)=N1 KBIHBGYYYFRDEA-UHFFFAOYSA-N 0.000 description 1
• PBFCTVPSJFFZSU-UHFFFAOYSA-N 5-ethyl-4-(iodomethyl)-2-(4-propan-2-ylphenyl)-1,3-oxazole Chemical compound ICC1=C(CC)OC(C=2C=CC(=CC=2)C(C)C)=N1 PBFCTVPSJFFZSU-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 102000004146 ATP citrate synthases Human genes 0.000 description 1
• 108090000662 ATP citrate synthases Proteins 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010059313 Anogenital warts Diseases 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 102000018619 Apolipoproteins A Human genes 0.000 description 1
• 108010027004 Apolipoproteins A Proteins 0.000 description 1
• 102000018616 Apolipoproteins B Human genes 0.000 description 1
• 108010027006 Apolipoproteins B Proteins 0.000 description 1
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 241000195940 Bryophyta Species 0.000 description 1
• XUQUNOFNOLPWSH-LTHQHPTJSA-N C/C=C(\c1ccccc1)/O/C(/c1ccc(C)cc1)=[NH+]/[O-] Chemical compound C/C=C(\c1ccccc1)/O/C(/c1ccc(C)cc1)=[NH+]/[O-] XUQUNOFNOLPWSH-LTHQHPTJSA-N 0.000 description 1
• YIXRGAIYTFCQLI-PVHODMMVSA-N CC(C)(C)[Si+](C)(C)OC[C@H](CO[C@H](CCC1)C[C@H]1OCc1c(C)[o]c(-c2cc(C)ccc2)n1)OCC#C Chemical compound CC(C)(C)[Si+](C)(C)OC[C@H](CO[C@H](CCC1)C[C@H]1OCc1c(C)[o]c(-c2cc(C)ccc2)n1)OCC#C YIXRGAIYTFCQLI-PVHODMMVSA-N 0.000 description 1
• RCLPUYNZEVAQHB-UOCPRXARSA-N CC(C)(C)[SiH-](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1OCc1ccccc1)OC Chemical compound CC(C)(C)[SiH-](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1OCc1ccccc1)OC RCLPUYNZEVAQHB-UOCPRXARSA-N 0.000 description 1
• KAHCLIOGUZERBY-ZVTBYLAHSA-N CC(C)(C)[Si](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1O)OC Chemical compound CC(C)(C)[Si](c1ccccc1)(c1ccccc1)OCC(CO[C@H](CCC1)C[C@H]1O)OC KAHCLIOGUZERBY-ZVTBYLAHSA-N 0.000 description 1
• QDMGUQRVUDTGDF-UHFFFAOYSA-N CC(CCC1)C/C1=[O]/Cc1c(C)[o]c(-c2cc(C)ccc2)n1 Chemical compound CC(CCC1)C/C1=[O]/Cc1c(C)[o]c(-c2cc(C)ccc2)n1 QDMGUQRVUDTGDF-UHFFFAOYSA-N 0.000 description 1
• MGLUFTIURPYNFJ-UHFFFAOYSA-N CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CCl Chemical compound CC1=CC=C(C=C1)C2=CC(=C(N2)C3=CC=CC=C3)CCl MGLUFTIURPYNFJ-UHFFFAOYSA-N 0.000 description 1
• RZDNNBPIXCXDEQ-ITAUSPCMSA-N CCCOC(CO)CO[C@H](CCC1)CC1OCc1c(C)[o]c(-c2cccc(C)c2)n1 Chemical compound CCCOC(CO)CO[C@H](CCC1)CC1OCc1c(C)[o]c(-c2cccc(C)c2)n1 RZDNNBPIXCXDEQ-ITAUSPCMSA-N 0.000 description 1
• PQVLCIAMIQFTCJ-UHFFFAOYSA-N CCCOC(COCC(CCC1)CC1OCc1c(CC)[o]c(-c2ccc(C(C)C)cc2)n1)C(O)=O Chemical compound CCCOC(COCC(CCC1)CC1OCc1c(CC)[o]c(-c2ccc(C(C)C)cc2)n1)C(O)=O PQVLCIAMIQFTCJ-UHFFFAOYSA-N 0.000 description 1
• MMGCWVVBEJSQHR-OADZCNSWSA-N CCCOC(CO[C@H](CCC1)CC1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 Chemical compound CCCOC(CO[C@H](CCC1)CC1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 MMGCWVVBEJSQHR-OADZCNSWSA-N 0.000 description 1
• YDPWWNONDZJGEV-XAGPSQNTSA-N CCOC(CO[C@H](CCC1)C[C@H]1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 Chemical compound CCOC(CO[C@H](CCC1)C[C@H]1O)CO[Si+](C(C)(C)C)(c1ccccc1)c1ccccc1 YDPWWNONDZJGEV-XAGPSQNTSA-N 0.000 description 1
• NGBNUEIXIRLOQR-UHFFFAOYSA-N CCc1c(CI)nc(-c2c(C)cccc2C)[o]1 Chemical compound CCc1c(CI)nc(-c2c(C)cccc2C)[o]1 NGBNUEIXIRLOQR-UHFFFAOYSA-N 0.000 description 1
• NDGKYAYGLGCZBS-UHFFFAOYSA-N CCc1c(COC(CCC2)CC2OCC(C(O)=O)OC)nc(-c2c(C)cccc2C)[o]1 Chemical compound CCc1c(COC(CCC2)CC2OCC(C(O)=O)OC)nc(-c2c(C)cccc2C)[o]1 NDGKYAYGLGCZBS-UHFFFAOYSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
• LJKFLYGWGNOMFS-UHFFFAOYSA-N Cc1c(COC(CCC2)CC2OCC(CO)OCC#C)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COC(CCC2)CC2OCC(CO)OCC#C)nc(-c2cccc(C)c2)[o]1 LJKFLYGWGNOMFS-UHFFFAOYSA-N 0.000 description 1
• KVNHEYRCTGTZOI-UHFFFAOYSA-N Cc1c(COC(CCC2)CC2OCC=C)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(COC(CCC2)CC2OCC=C)nc(-c2cc(C)ccc2)[o]1 KVNHEYRCTGTZOI-UHFFFAOYSA-N 0.000 description 1
• YIGOQTBYVANVNT-UHFFFAOYSA-N Cc1c(COC2CC(COCC(C(O)=O)OCC#CC)CCC2)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COC2CC(COCC(C(O)=O)OCC#CC)CCC2)nc(-c2cccc(C)c2)[o]1 YIGOQTBYVANVNT-UHFFFAOYSA-N 0.000 description 1
• FEPPYIYGXFNXOH-MDWZMJQESA-N Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OC/C=C/c2ccccc2)nc(-c2cccc(C)c2)[o]1 Chemical compound Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OC/C=C/c2ccccc2)nc(-c2cccc(C)c2)[o]1 FEPPYIYGXFNXOH-MDWZMJQESA-N 0.000 description 1
• HXAVIGJRKGAOAC-UHFFFAOYSA-N Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OCc2ccc(C(F)(F)F)cc2)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(COCC(CCC2)CC2OCC(C(O)=O)OCc2ccc(C(F)(F)F)cc2)nc(-c2cc(C)ccc2)[o]1 HXAVIGJRKGAOAC-UHFFFAOYSA-N 0.000 description 1
• PTQXRQMTWKVSOY-CVEARBPZSA-N Cc1c(CO[C@@H](CCC2)C[C@@H]2O)nc(-c2cc(C)ccc2)[o]1 Chemical compound Cc1c(CO[C@@H](CCC2)C[C@@H]2O)nc(-c2cc(C)ccc2)[o]1 PTQXRQMTWKVSOY-CVEARBPZSA-N 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
• 229920001268 Cholestyramine Polymers 0.000 description 1
• 229920002905 Colesevelam Polymers 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
• 208000032541 Epidermal naevus Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
• 102000019432 Galanin Human genes 0.000 description 1
• 101800002068 Galanin Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
• 102000051325 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
• 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
• 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
• 102000004366 Glucosidases Human genes 0.000 description 1
• 108010056771 Glucosidases Proteins 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 238000007341 Heck reaction Methods 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
• 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
• 102000002265 Human Growth Hormone Human genes 0.000 description 1
• 108010000521 Human Growth Hormone Proteins 0.000 description 1
• 239000000854 Human Growth Hormone Substances 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010058222 Hypertensive cardiomyopathy Diseases 0.000 description 1
• MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
• 108010057186 Insulin Glargine Proteins 0.000 description 1
• COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
• 229940122355 Insulin sensitizer Drugs 0.000 description 1
• 239000005909 Kieselgur Substances 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 102000000853 LDL receptors Human genes 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• 241000254158 Lampyridae Species 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 229910010084 LiAlH4 Inorganic materials 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
• 102100022119 Lipoprotein lipase Human genes 0.000 description 1
• 108010033266 Lipoprotein(a) Proteins 0.000 description 1
• 102000057248 Lipoprotein(a) Human genes 0.000 description 1
• 229940122014 Lyase inhibitor Drugs 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 229940124757 MC-4 agonist Drugs 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
• IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
• 241001024304 Mino Species 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• UULIGRNKXHCLQN-UHFFFAOYSA-N N-[[4-[[(4-amino-2-quinazolinyl)amino]methyl]cyclohexyl]methyl]-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 UULIGRNKXHCLQN-UHFFFAOYSA-N 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 201000009053 Neurodermatitis Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• IKGIOPLEUHSJBC-UHFFFAOYSA-N OCC(COC(CCC1)CC1OCc1ccccc1)O Chemical compound OCC(COC(CCC1)CC1OCc1ccccc1)O IKGIOPLEUHSJBC-UHFFFAOYSA-N 0.000 description 1
• 102000002512 Orexin Human genes 0.000 description 1
• 108010015181 PPAR delta Proteins 0.000 description 1
• 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 206010033733 Papule Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 102100040918 Pro-glucagon Human genes 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 206010038563 Reocclusion Diseases 0.000 description 1
• 208000017442 Retinal disease Diseases 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
• 229940123495 Squalene synthetase inhibitor Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
• 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
• 102000008200 Uncoupling Protein 3 Human genes 0.000 description 1
• 108010021098 Uncoupling Protein 3 Proteins 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000000260 Warts Diseases 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• 239000003392 amylase inhibitor Substances 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 229920006318 anionic polymer Polymers 0.000 description 1
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
• 229940127003 anti-diabetic drug Drugs 0.000 description 1
• 230000003178 anti-diabetic effect Effects 0.000 description 1
• 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• RCHHVVGSTHAVPF-ZPHPLDECSA-N apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 description 1
• 229940112930 apidra Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 150000001502 aryl halides Chemical class 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• BMWITAUNXBHIPO-OZZZDHQUSA-N benzenesulfonic acid;(2s,4s)-4-fluoro-1-[2-[(1-hydroxy-2-methylpropan-2-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound OS(=O)(=O)C1=CC=CC=C1.OCC(C)(C)NCC(=O)N1C[C@@H](F)C[C@H]1C#N BMWITAUNXBHIPO-OZZZDHQUSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 229940125388 beta agonist Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 229960000516 bezafibrate Drugs 0.000 description 1
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 150000004283 biguanides Chemical class 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
• 238000000451 chemical ionisation Methods 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
• 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
• 229950009226 ciglitazone Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960001214 clofibrate Drugs 0.000 description 1
• KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
• 239000008199 coating composition Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229960001152 colesevelam Drugs 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• GJYVZUKSNFSLCL-UHFFFAOYSA-N dichloromethanol Chemical compound OC(Cl)Cl GJYVZUKSNFSLCL-UHFFFAOYSA-N 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• AITJZYHNAKUCFP-UHFFFAOYSA-N diethyl 4-(4-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=C(F)C=C1 AITJZYHNAKUCFP-UHFFFAOYSA-N 0.000 description 1
• 238000005906 dihydroxylation reaction Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 201000011523 endocrine gland cancer Diseases 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• GYUCVQSNZFRDRL-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylbutanoate Chemical compound CCOC(=O)C(CC)P(=O)(OCC)OCC GYUCVQSNZFRDRL-UHFFFAOYSA-N 0.000 description 1
• BUPVIVDUPRDDFI-UHFFFAOYSA-N ethyl 2-diethoxyphosphorylpentanoate Chemical compound CCOC(=O)C(CCC)P(=O)(OCC)OCC BUPVIVDUPRDDFI-UHFFFAOYSA-N 0.000 description 1
• XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
• 229960000815 ezetimibe Drugs 0.000 description 1
• 229960001582 fenfluramine Drugs 0.000 description 1
• 229960002297 fenofibrate Drugs 0.000 description 1
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 125000001207 fluorophenyl group Chemical group 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000012041 food component Nutrition 0.000 description 1
• 239000005417 food ingredient Substances 0.000 description 1
• CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960003627 gemfibrozil Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 230000009229 glucose formation Effects 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• 230000004116 glycogenolysis Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
• 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 208000015210 hypertensive heart disease Diseases 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 239000012442 inert solvent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 108700039926 insulin glulisine Proteins 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229940045996 isethionic acid Drugs 0.000 description 1
• 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 229940099563 lactobionic acid Drugs 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 230000008604 lipoprotein metabolism Effects 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 201000002250 liver carcinoma Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 239000002697 lyase inhibitor Substances 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960000299 mazindol Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960001110 miglitol Drugs 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 208000008588 molluscum contagiosum Diseases 0.000 description 1
• SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 235000011929 mousse Nutrition 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• LXEDKSZTPGCEPU-UHFFFAOYSA-N n-[2-(3a-benzyl-2-methyl-3-oxo-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxamide Chemical compound O=C1N(C)N=C2CCN(C(=O)C(NC(=O)C3C(C4=CC=CC=C4CC3)N)C=3C=CC(Cl)=CC=3)CC21CC1=CC=CC=C1 LXEDKSZTPGCEPU-UHFFFAOYSA-N 0.000 description 1
• DIQDKUNCSVFGHH-UHFFFAOYSA-N n-[[4-[[(4-aminoquinazolin-2-yl)amino]methyl]cyclohexyl]methyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(N)=NC(NCC3CCC(CNS(=O)(=O)C=4C5=CC=CC=C5C=CC=4)CC3)=NC2=C1 DIQDKUNCSVFGHH-UHFFFAOYSA-N 0.000 description 1
• RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 230000002474 noradrenergic effect Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• 239000007764 o/w emulsion Substances 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 108060005714 orexin Proteins 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• CYZJKENQGYLGQC-UHFFFAOYSA-N oxadiazole-4,5-dione Chemical class O=C1ON=NC1=O CYZJKENQGYLGQC-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 229960003562 phentermine Drugs 0.000 description 1
• 208000017983 photosensitivity disease Diseases 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• 238000013492 plasmid preparation Methods 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 230000018656 positive regulation of gluconeogenesis Effects 0.000 description 1
• 230000000291 postprandial effect Effects 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 230000016438 regulation of fat cell differentiation Effects 0.000 description 1
• 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 210000005000 reproductive tract Anatomy 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 201000003385 seborrheic keratosis Diseases 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• 239000000952 serotonin receptor agonist Substances 0.000 description 1
• 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
• 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 229960004425 sibutramine Drugs 0.000 description 1
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 108091008012 small dense LDL Proteins 0.000 description 1
• UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
• 229960002218 sodium chlorite Drugs 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000004059 squalene synthase inhibitor Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• ZAOPBCHLHBOUPR-UHFFFAOYSA-N tert-butyl 1-[2-[di(propan-2-yl)amino]ethylcarbamoyl]-6-phenylmethoxy-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2C(C(=O)NCCN(C(C)C)C(C)C)N(C(=O)OC(C)(C)C)CCC2=CC=1OCC1=CC=CC=C1 ZAOPBCHLHBOUPR-UHFFFAOYSA-N 0.000 description 1
• GISPJYJZCWTSBA-UHFFFAOYSA-N tert-butyl-(3-methoxypropoxy)-diphenylsilane Chemical compound COCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C GISPJYJZCWTSBA-UHFFFAOYSA-N 0.000 description 1
• 229950004704 tesaglitazar Drugs 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 229950004514 torcetrapib Drugs 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
• 229960001641 troglitazone Drugs 0.000 description 1
• GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
• 239000007762 w/o emulsion Substances 0.000 description 1